Patterns of Immunohistochemical Expression of P53, BCL2, PTEN, and HER2/neu Tumor Markers in Specific Breast Cancer Lesions

OBJECTIVE: This study aimed to associate the expression of P53, BCL2, PTEN, and HER2/neu tumor markers in specific breast cancer lesions. METHODS: This study analyzed the immunohistochemical expression of P53, BCL2, PTEN, and HER2/neu tumor markers for 306 patients who presented with lesions. Tissue...

Descripción completa

Detalles Bibliográficos
Autores principales: Bealy, Mohamed Ahmed, Abugooda, Awad Aljeed, Ahmed, Ruba Mustafa Elsaid, Khalil, Nuha Abdel Rahman, Elasbali, Abdelbaset Mohamed, Mohamed, Ghorashy Eltayeb Yousif, Eltom, Faris Merghani, Ahmed, Hussain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592210/
https://www.ncbi.nlm.nih.gov/pubmed/36299777
http://dx.doi.org/10.1155/2022/2026284
Descripción
Sumario:OBJECTIVE: This study aimed to associate the expression of P53, BCL2, PTEN, and HER2/neu tumor markers in specific breast cancer lesions. METHODS: This study analyzed the immunohistochemical expression of P53, BCL2, PTEN, and HER2/neu tumor markers for 306 patients who presented with lesions. Tissue blocks and patients' identification data were retrieved from the department of pathology, AL Madinah Almonwarah hospital, Al Madinah, UAE. RESULTS: Of the 306 patients, 104 had benign lesions and 202 had malignancy (including 194 females and 6 males). Most females were presented with invasive ductal carcinoma (IDC), followed by infiltrating ductal carcinoma, and invasive lobular carcinoma (ILC), representing 70%, 23.2%, and 3.7%, respectively. Positive P53, BCL2, PTEN, and HER2 were identified in 20.8%, 11.9%, 91%, and 18.3%, respectively. CONCLUSION: : The expression of P53, BCL2, PTEN, and HER2/neu tumor markers among Saudi patients with breast cancer is relatively similar in many parts of the world.

Ejemplares similares